ECSP10010631A - Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer - Google Patents

Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer

Info

Publication number
ECSP10010631A
ECSP10010631A EC2010010631A ECSP10010631A ECSP10010631A EC SP10010631 A ECSP10010631 A EC SP10010631A EC 2010010631 A EC2010010631 A EC 2010010631A EC SP10010631 A ECSP10010631 A EC SP10010631A EC SP10010631 A ECSP10010631 A EC SP10010631A
Authority
EC
Ecuador
Prior art keywords
methods
release factor
cancer treatment
corticotropine
corticotropine release
Prior art date
Application number
EC2010010631A
Other languages
English (en)
Spanish (es)
Inventor
Stephen Evans-Freke
Original Assignee
Neutron Row
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neutron Row filed Critical Neutron Row
Publication of ECSP10010631A publication Critical patent/ECSP10010631A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/2228Corticotropin releasing factor [CRF] (Urotensin)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EC2010010631A 2008-04-30 2010-11-24 Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer ECSP10010631A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4929208P 2008-04-30 2008-04-30
US9480608P 2008-09-05 2008-09-05

Publications (1)

Publication Number Publication Date
ECSP10010631A true ECSP10010631A (es) 2011-02-28

Family

ID=41119761

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010631A ECSP10010631A (es) 2008-04-30 2010-11-24 Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer

Country Status (17)

Country Link
US (1) US20100113341A1 (https=)
EP (1) EP2259793A2 (https=)
JP (1) JP2011519375A (https=)
KR (1) KR20110021820A (https=)
CN (1) CN102036680A (https=)
AU (1) AU2009241813A1 (https=)
CA (1) CA2722426A1 (https=)
CO (1) CO6300959A2 (https=)
CR (1) CR11762A (https=)
EC (1) ECSP10010631A (https=)
IL (1) IL209005A0 (https=)
MX (1) MX2010011882A (https=)
NI (1) NI201000185A (https=)
NZ (1) NZ588877A (https=)
RU (1) RU2010148803A (https=)
WO (1) WO2009134396A2 (https=)
ZA (1) ZA201007729B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057962A2 (en) * 2008-11-19 2010-05-27 Neutron Limited Crf conjugates with extended half-lives
CA2766322A1 (en) * 2009-06-24 2010-12-29 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the treatment of cancer

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2852054A (en) * 1956-11-23 1958-09-16 Motley Murat Brunson Container and closure therefor
US4312523A (en) * 1979-10-29 1982-01-26 Paco Packaging Incorporated Label for container having pharmaceutical product therein
US4415558A (en) 1981-06-08 1983-11-15 The Salk Institute For Biological Studies CRF And analogs
AU9054582A (en) 1982-09-29 1984-04-24 Lederis, K.P., Mac Cannell, K.L.:ichikawa, T:river, J.E. Urotensin peptides
US4528189A (en) 1983-02-03 1985-07-09 The Salk Institute For Biological Studies Urotensin peptides
US4489163A (en) * 1983-04-14 1984-12-18 The Salk Institute For Biological Studies rCRF and analogs
US5391485A (en) * 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) * 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) * 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするdna
US5342940A (en) * 1989-05-27 1994-08-30 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, process for preparing the same
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5229940A (en) * 1992-01-29 1993-07-20 Conoco Inc. Method of extracting three dimensional information from a grid of two dimensional seismic data
US5360352A (en) * 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5780431A (en) * 1996-09-20 1998-07-14 Neurobiological Technologies, Inc. Pharmaceutical formulations of corticotropin releasing factor having improved stability in liquid form
US6319900B1 (en) * 1999-09-21 2001-11-20 The Regents Of The University Of California Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs
CN1361180A (zh) * 2000-12-26 2002-07-31 上海博德基因开发有限公司 一种新的多肽——促肾上腺皮质激素释放因子8.8和编码这种多肽的多核苷酸
CN1382700A (zh) * 2001-04-26 2002-12-04 上海博德基因开发有限公司 一种多肽——促肾上腺皮质激素释放因子-12.87和编码这种多肽的多核苷酸
CA2358177A1 (en) * 2001-10-03 2003-04-03 Ted Ramsay Label for pharmaceutical prescriptions
WO2004100997A2 (en) * 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
MXPA06014021A (es) * 2004-06-04 2007-02-08 Pfizer Prod Inc Procedimiento para tratar crecimiento celular anormal.
BRPI0513062A (pt) * 2004-07-08 2008-04-22 Aimsco Ltd composição farmacêutica, método de estimular a produção de pomc em um paciente, usos de um peptìdeo de crf isolado e de um peptìdeo de pomc isolado, e, métodos de tratamento para uma doença, de produzir crf e de tratamento curativo, melhorador ou profilático de uma doença
JP2006036013A (ja) * 2004-07-27 2006-02-09 Yamaha Motor Co Ltd 自動二輪車
US7311205B2 (en) * 2005-01-25 2007-12-25 Target Brands, Inc. Pharmacy bottle system including label
US20100203048A1 (en) * 2008-04-30 2010-08-12 Stephen Evans-Freke Methods of using corticotropin-releasing factor for the use of the treatment of cancer

Also Published As

Publication number Publication date
NI201000185A (es) 2013-04-22
WO2009134396A2 (en) 2009-11-05
CO6300959A2 (es) 2011-07-21
JP2011519375A (ja) 2011-07-07
US20100113341A1 (en) 2010-05-06
EP2259793A2 (en) 2010-12-15
CN102036680A (zh) 2011-04-27
ZA201007729B (en) 2014-02-26
NZ588877A (en) 2012-08-31
CA2722426A1 (en) 2009-11-05
CR11762A (es) 2011-04-26
AU2009241813A1 (en) 2009-11-05
KR20110021820A (ko) 2011-03-04
IL209005A0 (en) 2011-01-31
MX2010011882A (es) 2011-02-25
RU2010148803A (ru) 2012-06-10
WO2009134396A3 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
AR055038A1 (es) Metodo y compuesto para tratar enfermedades vasculares perifericas
CY1125948T1 (el) Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου
MX2020009773A (es) Terapia de combinacion.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
MX2017006312A (es) Metodos para el tratamiento tumoral utilizando el anticuerpo biespecifico cd3xcd20.
MX2016004580A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CL2011000099A1 (es) Uso de una beta-defensina humana en la manufactura de un medicamento que sirve para el tratamiento de una enfermedad intestinal inflamatoria.
EA201491011A1 (ru) Способы лечения с помощью ингибитора гамма-интерферона
MX2020001727A (es) Terapia de combinacion.
PH12013500857A1 (en) Methods and compositions for treating hiv-associated diarrhea
CY1116216T1 (el) Μεθοδος θεραπειας ασθενειας αποθηκευσης γλυκογονου
MX2023000187A (es) Dosificacion de vibegron para el tratamiento de vejiga sobreactiva.
BR112023019156A2 (pt) Inalador pressurizado dosimetrado e formulação para uso em um método para tratar uma reação alérgica aguda
UY33740A (es) Método para tratar el cáncer de mama y cáncer de ovarios
DOP2013000131A (es) Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek
ECSP10010631A (es) Metodos para utilizar un factor de liberación de corticotropina para el tratamiento de cáncer
DK1971338T3 (da) Kombination af ZD6474 og pemetrexed
MX2021001764A (es) Terapia de combinacion.
EA202091653A1 (ru) Миноциклин для лечения воспалительных заболеваний кожи
AR076479A1 (es) Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i
PE20200889A1 (es) METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa)
NO20064754L (no) Kombinasjonsterapi
ATE540920T1 (de) Aminobenzocycloheptenderivate, verfahren zu deren herstellung und deren verwendung in der therapie
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek
UA102098C2 (ru) Применение кортикотропин-рилизинг фактора для лечения рака